ESR1 and cancer: The findings of the current study reveal that tamoxifen rechallenge may promote proliferation and clonogenicity but decrease metastatic potential in a group of cancer cells, which are present in the ER+ breast tumor mass and exhibit higher cytotoxic tolerance to tamoxifen (i.e., primary challenge).